AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02836249
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF placebo tablet administered orally once daily
Trial: NCT03950856
Drug: V114
RxNorm normalized name: Pneumococcal 15-valent Conjugate Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
Trial: NCT03950856
Drug: Prevnar 13™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
Trial: NCT04104789
Drug: Kovanaze Nasal Spray
RxNorm normalized name: Kovanaze Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal local anesthetic
Trial: NCT04429919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
Trial: NCT02160808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02194153
Drug: Metalyse weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01395745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered weekly via subcutaneous injection for 52 weeks
Trial: NCT02038036
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
Trial: NCT01573117
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Trial: NCT01972659
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
Trial: NCT02410187
Drug: systemic therapy (chemotherapy, hormon therapy, target therapy etc)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.
Trial: NCT00834197
Drug: REMERON SolTab® 15 mg Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose non-fasting
Trial: NCT00988247
Drug: Placebo Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
Trial: NCT03802396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
Trial: NCT01107886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04194242
Drug: HEC96719 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
Trial: NCT04194242
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
Trial: NCT01471665
Drug: GSK2190915 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
Trial: NCT02724202
Drug: 5-flurorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
Trial: NCT03262961
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01246960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT01246960
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT02829372
Drug: CD3/HER2 bispecific monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses, IV on day 1 and 15 of each 28 day cycle
Trial: NCT00980044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Medication
Trial: NCT01471665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily for up to 16 days.
Trial: NCT01409096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active medication in appearance.
Trial: NCT02301897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Trial: NCT01605994
Drug: Placebo matching with BMS-933043
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01605994
Drug: Antacid Buffer Predose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01347814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic (Sugar) pill-Placebo
Trial: NCT00314977
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
Trial: NCT00314977
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
Trial: NCT01067807
Drug: 25 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
Trial: NCT01067807
Drug: 25 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
Trial: NCT01067807
Drug: 25 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Trial: NCT01067807
Drug: 50 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Trial: NCT03474276
Drug: Azythromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
Trial: NCT03116126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive oral daily tablet
Trial: NCT00004128
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03135860
Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
Trial: NCT01702298
Drug: Sitagliptin 100 mg/simvastatin 40 mg FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
Trial: NCT02522767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02494596
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Trial: NCT01186757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00573768
Drug: Diclofenac diethylamine 2.32% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac diethylamine 2.32% gel twice daily
Trial: NCT00573768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 2 times daily
Trial: NCT00573768
Drug: Diclofenac diethylamine 2.32% gel / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
Trial: NCT02576288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-inflammatory properties
Trial: NCT04183686
Drug: Placebo (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo; soft capsules for oral use.
Trial: NCT04183686
Drug: Placebo (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of matching placebo; soft capsules for oral use.
Trial: NCT02321475
Drug: EGb761®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03322566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice daily.
Trial: NCT03202394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Trial: NCT02736071
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Trial: NCT02736071
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
Trial: NCT02736071
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
Trial: NCT03503409
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
Trial: NCT02448381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Trial: NCT00054262
Drug: T900607
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00833690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
Trial: NCT00833690
Drug: inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
Trial: NCT00833690
Drug: inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
Trial: NCT01438918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day for 2 years
Trial: NCT02011347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00645658
Drug: Testim, 1% testosterone gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
Trial: NCT02947048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00304161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 to 80 mg orally once daily for 8 weeks
Trial: NCT04316416
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
Trial: NCT04256655
Drug: cohort 1 0.225g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Trial: NCT04256655
Drug: Cohort 2 0.75g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Trial: NCT04256655
Drug: Cohort 3 2.25 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Trial: NCT03728478
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
Trial: NCT03728478
Drug: Intra-articular corticosteroid injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
Trial: NCT02287779
Drug: SHP626
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02287779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02577809
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mcg Fentanyl added to the spinal anaesthetic
Trial: NCT02577809
Drug: Hyperbaric Bupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8ml 0.5% spinal bupivicaine with dextrose
Trial: NCT02577809
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg Indomethacin suppository
Trial: NCT01169779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT03477422
Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)
RxNorm normalized name: PHOSPHORIC ACID 1500 mg in 10 L / BENZALKONIUM CHLORIDE 400 mg in 10 L / N-ALKYL ETHYLBENZYL DIMETHYL AMMONIUM CHLORIDE (C12-C14) 400 mg in 10 L TOPICAL LIQUID [StepSept CSE-200]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
Trial: NCT04049513
Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
Trial: NCT01188967
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 60 mg/day for a treatment period six weeks
Trial: NCT01188967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00189475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00244985
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00416507
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02105129
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
Trial: NCT02105129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00759395
Drug: AZD2327
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, Daily
Trial: NCT00759395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, Daily
Trial: NCT00509288
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Trial: NCT02259595
Drug: HPN-07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-1,500 mg oral capsules administered in a single dose
Trial: NCT02259595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral capsule
Trial: NCT01350076
Drug: conventional liberal fluid regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
Trial: NCT01350076
Drug: restricted fluid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index
Trial: NCT01169779
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
Trial: NCT01082939
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
Trial: NCT01466088
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
Trial: NCT05663684
Drug: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic
Trial: NCT00829244
Drug: GONAL f® prefilled pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
Trial: NCT00829244
Drug: GONAL f® prefilled pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
Trial: NCT03573050
Drug: RIV-TDS 13.3 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
Trial: NCT03573050
Drug: Exelon® 13.3 mg/24 hours transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours